Michael Roger Harrison | Scholars@Duke

Michael Roger Harrison
Associate Professor of Medicine

Current Appointments & Affiliations

Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2021
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2011

Contact Information

michael.harrison@duke.edu

Background
Education, Training, & Certifications
- residency, Medicine, Tulane University 2004 - 2007
- M.D., Tulane University 2004
Previous Appointments & Affiliations
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2018 - 2021
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2011 - 2018
Research
Selected Grants
External Relationships
- Aveo Oncology
- Exelixis, Inc.
- Janssen Oncology
- Sanofi
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Chen, Yu-Wei, Matthew D. Tucker, Landon C. Brown, Hesham A. Yasin, Kristin K. Ancell, Andrew J. Armstrong, Kathryn E. Beckermann, et al. “The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.” Cancers 14, no. 15 (August 2022): 3830. https://doi.org/10.3390/cancers14153830.
    Full Text
  - Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Subha Bakthavatsalam, et al. “Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.” Prostate 82, no. 7 (May 2022): 858–66. https://doi.org/10.1002/pros.24329.
    Full Text Link to Item
  - Brown, Landon C., Susan Halabi, Jason A. Somarelli, Michael Humeniuk, Yuan Wu, Taofik Oyekunle, Lauren Howard, et al. “A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.” Prostate Cancer Prostatic Dis 25, no. 4 (April 2022): 762–69. https://doi.org/10.1038/s41391-022-00524-7.
    Full Text Link to Item
  - Hanson, Erik D., Mohamdod Alzer, Jackson Carver, Cameron K. Stopforth, Alexander R. Lucas, Young E. Whang, Matthew I. Milowsky, et al. “Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis, March 19, 2022. https://doi.org/10.1038/s41391-022-00523-8.
    Full Text Link to Item
  - Harrison, Michael R., Paul G. Davis, Michel G. Khouri, David B. Bartlett, Rajan T. Gupta, Andrew J. Armstrong, Megan A. McNamara, et al. “A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).” Prostate Cancer Prostatic Dis 25, no. 1 (March 2022): 58–64. https://doi.org/10.1038/s41391-022-00519-4.
    Full Text Link to Item
  - Costello, Brian A., Nrupen A. Bhavsar, Yousef Zakharia, Sumanta K. Pal, Ulka Vaishampayan, Heather Jim, Mayer N. Fishman, et al. “A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.” Clin Genitourin Cancer 20, no. 1 (February 2022): 1–10. https://doi.org/10.1016/j.clgc.2021.07.002.
    Full Text Link to Item
  - Tykodi, Scott S., Lucio N. Gordan, Robert S. Alter, Edward Arrowsmith, Michael R. Harrison, Ivor Percent, Rakesh Singal, et al. “Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.” J Immunother Cancer 10, no. 2 (February 2022). https://doi.org/10.1136/jitc-2021-003844.
    Full Text Link to Item
  - Autio, Karen A., Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, et al. “Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.” Eur Urol Open Sci 34 (December 2021): 70–78. https://doi.org/10.1016/j.euros.2021.09.015.
    Full Text Link to Item
  - Bitting, Rhonda L., Patrick Healy, Daniel J. George, Monika Anand, Sung Kim, Tina Mayer, Carol Winters, et al. “Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.” Eur Urol Oncol 4, no. 6 (December 2021): 948–54. https://doi.org/10.1016/j.euo.2020.01.005.
    Full Text Link to Item
  - Dzimitrowicz, Hannah, Elizabeth Esterberg, LaStella Miles, Giovanni Zanotti, Azah Borham, and Michael R. Harrison. “Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma.” Cancer Medicine 10, no. 24 (December 2021): 8891–98. https://doi.org/10.1002/cam4.4407.
    Full Text
  - Hirsch, Laure, Nieves Martinez Chanza, Subrina Farah, Wanling Xie, Ronan Flippot, David A. Braun, Nityam Rathi, et al. “Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.” Jama Oncol 7, no. 12 (December 1, 2021): 1815–23. https://doi.org/10.1001/jamaoncol.2021.4544.
    Full Text Link to Item
  - Tucker, Matthew D., Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, et al. “Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.” Biomark Res 9, no. 1 (November 3, 2021): 80. https://doi.org/10.1186/s40364-021-00334-4.
    Full Text Link to Item
  - Rose, Tracy L., Michael R. Harrison, Allison M. Deal, Sundhar Ramalingam, Young E. Whang, Blaine Brower, Mary Dunn, et al. “Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.” J Clin Oncol 39, no. 28 (October 1, 2021): 3140–48. https://doi.org/10.1200/JCO.21.01003.
    Full Text Link to Item
  - Hanson, Erik D., Cameron K. Stopforth, Mohamdod Alzer, Jackson Carver, Alexander R. Lucas, Young E. Whang, Matthew I. Milowsky, et al. “Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer.” Prostate Cancer Prostatic Dis 24, no. 3 (September 2021): 725–32. https://doi.org/10.1038/s41391-020-00317-w.
    Full Text Link to Item
  - George, Daniel J., Susan Halabi, Elisabeth I. Heath, A Oliver Sartor, Guru P. Sonpavde, Devika Das, Rhonda L. Bitting, et al. “A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.” Cancer 127, no. 16 (August 15, 2021): 2954–65. https://doi.org/10.1002/cncr.33589.
    Full Text Link to Item
  - Harrison, Michael R., Brian A. Costello, Nrupen A. Bhavsar, Ulka Vaishampayan, Sumanta K. Pal, Yousef Zakharia, Heather S. L. Jim, et al. “Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).” Cancer 127, no. 13 (July 1, 2021): 2204–12. https://doi.org/10.1002/cncr.33494.
    Full Text Open Access Copy Link to Item
  - Yu, Evan Y., Daniel P. Petrylak, Peter H. O’Donnell, Jae-Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, et al. “Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology 22, no. 6 (June 2021): 872–82. https://doi.org/10.1016/s1470-2045(21)00094-2.
    Full Text
  - Koontz, Bridget F., Karen E. Hoffman, Susan Halabi, Patrick Healy, Monika Anand, Daniel J. George, Michael R. Harrison, et al. “Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.” Int J Radiat Oncol Biol Phys 109, no. 5 (April 1, 2021): 1271–78. https://doi.org/10.1016/j.ijrobp.2020.11.059.
    Full Text Link to Item
  - Laccetti, Andrew L., Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, et al. “Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.” Cancer Med 10, no. 7 (April 2021): 2341–49. https://doi.org/10.1002/cam4.3812.
    Full Text Link to Item
  - Brown, Landon C., Matthew D. Tucker, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew K. Labriola, et al. “LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.” J Immunother Cancer 9, no. 3 (March 2021). https://doi.org/10.1136/jitc-2020-001792.
    Full Text Open Access Copy Link to Item
  - Dinan, Michaela A., Mihaela V. Georgieva, Yanhong Li, Tian Zhang, Michael Harrison, Rahul Shenolikar, and Charles D. Scales. “Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.” J Geriatr Oncol 12, no. 2 (March 2021): 298–304. https://doi.org/10.1016/j.jgo.2020.08.005.
    Full Text Link to Item
  - Tannir, Nizar M., Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel, Jean-Christophe Pignon, et al. “Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.” Clin Cancer Res 27, no. 1 (January 1, 2021): 78–86. https://doi.org/10.1158/1078-0432.CCR-20-2063.
    Full Text Link to Item
  - Brown, Landon C., Jason Zhu, Matthew K. Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, et al. “PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.” Clin Genitourin Cancer 18, no. 6 (December 2020): 509–13. https://doi.org/10.1016/j.clgc.2020.03.020.
    Full Text Link to Item
  - Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.
    Full Text Link to Item
  - Zhang, Tian, Michael R. Harrison, Peter H. O’Donnell, Ajjai S. Alva, Noah M. Hahn, Leonard J. Appleman, Jeremy Cetnar, et al. “A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.” Cancer 126, no. 20 (October 15, 2020): 4485–97. https://doi.org/10.1002/cncr.33067.
    Full Text Open Access Copy Link to Item
  - Narayan, Vivek, Michael Harrison, Heather Cheng, Stacey Kenfield, Rahul Aggarwal, Daniel Kwon, Rana McKay, et al. “Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.” Urol Oncol 38, no. 3 (March 2020): 83–93. https://doi.org/10.1016/j.urolonc.2019.10.006.
    Full Text Link to Item
  - Martinez Chanza, Nieves, Wanling Xie, Majd Issa, Hannah Dzimitrowicz, Abhishek Tripathi, Benoit Beuselinck, Elaine Lam, et al. “Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.” J Immunother Cancer 8, no. 1 (March 2020). https://doi.org/10.1136/jitc-2020-000538.
    Full Text Link to Item
  - Meleis, Laura, Russell Moore, Brant A. Inman, and Michael R. Harrison. “Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.” J Oncol Pharm Pract 26, no. 2 (March 2020): 330–37. https://doi.org/10.1177/1078155219845434.
    Full Text Open Access Copy Link to Item
  - Armstrong, Andrew J., Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, Patrick Healy, et al. “Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.” Jco Precis Oncol 4 (2020). https://doi.org/10.1200/PO.20.00200.
    Full Text Link to Item
  - Chiang, Ryan S., Ashton A. Connor, Brant A. Inman, Wen-Chi Foo, David N. Howell, John F. Madden, Matthew J. Ellis, Aparna S. Rege, and Michael R. Harrison. “Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor.” Case Rep Urol 2020 (2020): 8881841. https://doi.org/10.1155/2020/8881841.
    Full Text Open Access Copy Link to Item
  - Holl, Eda K., Megan A. McNamara, Patrick Healy, Monika Anand, Raoul S. Concepcion, Coleman D. Breland, Igor Dumbudze, et al. “Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.” Prostate Cancer Prostatic Dis 22, no. 4 (December 2019): 588–92. https://doi.org/10.1038/s41391-019-0144-3.
    Full Text Link to Item
  - Motzer, Robert J., Eric Jonasch, M Dror Michaelson, Lakshminarayanan Nandagopal, John L. Gore, Saby George, Ajjai Alva, et al. “NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.” J Natl Compr Canc Netw 17, no. 11 (November 1, 2019): 1278–85. https://doi.org/10.6004/jnccn.2019.0054.
    Full Text Link to Item
  - George, Daniel J., Susan Halabi, Patrick Healy, Ian Barak, Carolyn Winters, Monika Anand, Rhonda Wilder, et al. “Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.” Prostate 79, no. 15 (November 2019): 1752–61. https://doi.org/10.1002/pros.23899.
    Full Text Link to Item
  - Motzer, Robert J., Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, et al. “Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.” Lancet Oncol 20, no. 10 (October 2019): 1370–85. https://doi.org/10.1016/S1470-2045(19)30413-9.
    Full Text Link to Item
  - Tucker, Matthew D., Jason Zhu, Daniele Marin, Rajan T. Gupta, Santosh Gupta, William R. Berry, Sundhar Ramalingam, et al. “Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.” Cancer Med 8, no. 10 (August 2019): 4644–55. https://doi.org/10.1002/cam4.2375.
    Full Text Link to Item
  - Labriola, Matthew K., Kristen A. Batich, Jason Zhu, Megan A. McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.” Clin Genitourin Cancer 17, no. 3 (June 2019): e513–21. https://doi.org/10.1016/j.clgc.2019.01.017.
    Full Text Link to Item
  - Martínez Chanzá, Nieves, Wanling Xie, Mehmet Asim Bilen, Hannah Dzimitrowicz, Jarred Burkart, Daniel M. Geynisman, Archana Balakrishnan, et al. “Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.” Lancet Oncol 20, no. 4 (April 2019): 581–90. https://doi.org/10.1016/S1470-2045(18)30907-0.
    Full Text Link to Item
  - Bruns, Nicholas E., Ian C. Glenn, Domenic R. Craner, Steve J. Schomisch, Michael R. Harrison, and Todd A. Ponsky. “Magnetic compression anastomosis (magnamosis) in a porcine esophagus: Proof of concept for potential application in esophageal atresia.” J Pediatr Surg 54, no. 3 (March 2019): 429–33. https://doi.org/10.1016/j.jpedsurg.2018.09.014.
    Full Text Link to Item
  - Ramalingam, S., M. Walker, D. J. George, and M. R. Harrison. “Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival.” Kidney Cancer 3, no. 2 (January 1, 2019): 133–40. https://doi.org/10.3233/KCA-190059.
    Full Text
  - Khouri, Michel G., and Michael R. Harrison. “Look and You Will Find It: Practical Considerations for Improving Multidisciplinary Management of Androgen-Deprivation Therapy-Induced Cardiometabolic Toxicity.” J Oncol Pract 14, no. 10 (October 2018): 591–93. https://doi.org/10.1200/JOP.18.00543.
    Full Text Link to Item
  - Rini, B. I., N. M. Tannir, B. Escudier, D. F. McDermott, M. O. Grimm, C. Porta, T. Powles, et al. “Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii309–10. https://doi.org/10.1093/annonc/mdy283.084.
    Full Text
  - Brousell, Steven C., Joseph J. Fantony, Megan G. Van Noord, Michael R. Harrison, and Brant A. Inman. “Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy.” Core Evid 13 (2018): 1–12. https://doi.org/10.2147/CE.S118670.
    Full Text Link to Item
  - Gopalakrishna, Ajay, Thomas A. Longo, Joseph J. Fantony, Michael R. Harrison, and Brant A. Inman. “Physical activity patterns and associations with health-related quality of life in bladder cancer survivors.” Urol Oncol 35, no. 9 (September 2017): 540.e1-540.e6. https://doi.org/10.1016/j.urolonc.2017.04.016.
    Full Text Link to Item
  - Motzer, Robert J., Eric Jonasch, Neeraj Agarwal, Sam Bhayani, William P. Bro, Sam S. Chang, Toni K. Choueiri, et al. “Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 6 (June 2017): 804–34. https://doi.org/10.6004/jnccn.2017.0100.
    Full Text Link to Item
  - Ramalingam, Sundhar, Michael S. Humeniuk, Rachel Hu, Julia Rasmussen, Patrick Healy, Yuan Wu, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.” Urol Oncol 35, no. 6 (June 2017): 418–24. https://doi.org/10.1016/j.urolonc.2016.12.016.
    Full Text Link to Item
  - Bhavsar, Nrupen A., Michael R. Harrison, Bradford R. Hirsch, Patricia Creel, Steve P. Wolf, Greg P. Samsa, Amy P. Abernethy, Ronit Simantov, Azah Borham, and Daniel J. George. “Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.” Cancer Invest 35, no. 5 (May 28, 2017): 333–44. https://doi.org/10.1080/07357907.2017.1289215.
    Full Text Link to Item
  - Madden-Fuentes, Ramiro Jose, Bridget F. Koontz, Michael R. Harrison, Daniel J. George, Brittany Davidson, Brian F. Gilmore, Judd W. Moul, Christopher Mantyh, and Andrew C. Peterson. “How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?” Oncology (Williston Park) 31, no. 4 (April 15, 2017): 286–94.
    Link to Item
  - Inman, Brant A., Thomas A. Longo, Sundhar Ramalingam, and Michael R. Harrison. “Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.” Clin Cancer Res 23, no. 8 (April 15, 2017): 1886–90. https://doi.org/10.1158/1078-0432.CCR-16-1417.
    Full Text Link to Item
  - Ramalingam, Sundhar, richard Bloomfield, daniel George, zubin Eapen, and M. R. Harrison. “Mobile Health Applications in Patients With Metastatic Renal Cell Carcinoma.” Kidney Cancer Journal 15, no. 4 (2017): 101–5.
    Open Access Copy Link to Item
  - Ramalingam, Sundhar, Adva Eisenberg, Wen Chi Foo, Jennifer Freedman, Andrew J. Armstrong, Larry G. Moss, and Michael R. Harrison. “Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.” Int J Urol 23, no. 12 (December 2016): 1038–41. https://doi.org/10.1111/iju.13225.
    Full Text Link to Item
  - Choueiri, Toni K., Mayer N. Fishman, Bernard Escudier, David F. McDermott, Charles G. Drake, Harriet Kluger, Walter M. Stadler, et al. “Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.” Clin Cancer Res 22, no. 22 (November 15, 2016): 5461–71. https://doi.org/10.1158/1078-0432.CCR-15-2839.
    Full Text Link to Item
  - Gopalakrishna, Ajay, Thomas A. Longo, Joseph J. Fantony, Uma Doshi, Michael R. Harrison, Megan Van Noord, and Brant A. Inman. “High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis.” Urol Oncol 34, no. 9 (September 2016): 407–14. https://doi.org/10.1016/j.urolonc.2016.05.009.
    Full Text Link to Item
  - Glass, Oliver K., Sundhar Ramalingam, and Michael R. Harrison. “Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss.” Clin Adv Hematol Oncol 14, no. 6 (June 2016): 436–46.
    Link to Item
  - Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, et al. “Development of a Novel c-MET-Based CTC Detection Platform.” Mol Cancer Res 14, no. 6 (June 2016): 539–47. https://doi.org/10.1158/1541-7786.MCR-16-0011.
    Full Text Open Access Copy Link to Item
  - Harrison, M. R., and S. Ramalingam. “Novel Androgen Receptor Signaling Inhibitors for Nonmetastatic Castration-Resistant Prostate Cancer: The Light at the End of the Tunnel-or an Oncoming Train?” Oncology (Williston Park, N.Y.) 30, no. 4 (April 1, 2016): 345–47.
  - Motzer, Robert J., Bernard Escudier, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, et al. “Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.” New England Journal of Medicine 373, no. 19 (November 5, 2015): 1803–13. https://doi.org/10.1056/nejmoa1510665.
    Full Text
  - Mitchell, Aaron P., Michael R. Harrison, Mark S. Walker, Daniel J. George, Amy P. Abernethy, and Bradford R. Hirsch. “Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.” J Oncol Pract 11, no. 6 (November 2015): 491–97. https://doi.org/10.1200/JOP.2015.004929.
    Full Text Link to Item
  - Ramalingam, Sundhar, Kathryn I. Pollak, Leah L. Zullig, and Michael R. Harrison. “What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis?” Oncology (Williston Park) 29, no. 9 (September 2015): 680–94.
    Link to Item
  - Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Michael R. Harrison, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.” Clin Genitourin Cancer 13, no. 4 (August 2015): 392–99. https://doi.org/10.1016/j.clgc.2015.01.004.
    Full Text Link to Item
  - Mitchell, Aaron P., Bradford R. Hirsch, Michael R. Harrison, Amy P. Abernethy, and Daniel J. George. “Deferred systemic therapy in patients with metastatic renal cell carcinoma.” Clin Genitourin Cancer 13, no. 3 (June 2015): e159–66. https://doi.org/10.1016/j.clgc.2014.12.017.
    Full Text Link to Item
  - Stover, J. T., R. A. Moore, K. Davis, M. R. Harrison, and A. J. Armstrong. “Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis 18, no. 2 (June 2015): 161–66. https://doi.org/10.1038/pcan.2015.7.
    Full Text Link to Item
  - Davis, Kristen, Sarah Wood, Emily Dill, Yuri Fesko, Rhonda L. Bitting, Michael R. Harrison, Andrew J. Armstrong, Judd W. Moul, and Daniel J. George. “Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.” Clin J Oncol Nurs 19, no. 3 (June 2015): 297–303. https://doi.org/10.1188/15.CJON.297-303.
    Full Text Link to Item
  - Motzer, Robert J., Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, Ulka N. Vaishampayan, et al. “Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.” J Clin Oncol 33, no. 13 (May 1, 2015): 1430–37. https://doi.org/10.1200/JCO.2014.59.0703.
    Full Text Link to Item
  - Harrison, Michael R., and Andrew J. Armstrong. “Burden of disease matters when it comes to systemic therapy for prostate cancer.” Eur Urol 67, no. 3 (March 2015): 448–50. https://doi.org/10.1016/j.eururo.2014.02.032.
    Full Text Link to Item
  - Choueri, Toni K., Mayer N. Fishman, Bernard Escudier, David F. McDermott, Harriet Kluger, Walter M. Stadler, Jose L. Perez-Gracia, et al. “IMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC): ASSOCIATION OF BIOMARKERS WITH CLINICAL OUTCOMES.” Asia Pacific Journal of Clinical Oncology 11 (2015): 119–119.
    Link to Item
  - Plimack, Elizabeth R., Hans J. Hammers, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, et al. “UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC).” Asia Pacific Journal of Clinical Oncology 11 (2015): 129–129.
    Link to Item
  - Choueiri, T., M. N. Fishman, B. Escudier, J. J. Kim, H. Kluger, W. M. Stadler, J. L. Perez-Garcia, et al. “1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL.” Ann Oncol 25, no. suppl_4 (September 1, 2014): iv362. https://doi.org/10.1093/annonc/mdu342.4.
    Full Text Link to Item
  - Hirsch, Bradford R., Michael R. Harrison, Daniel J. George, Mark S. Walker, Connie Chen, Beata Korytowsky, Edward Stepanski, and Amy P. Abernethy. “Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.” Med Oncol 31, no. 9 (September 2014): 156. https://doi.org/10.1007/s12032-014-0156-8.
    Full Text Link to Item
  - Harrison, Michael R., and Lee W. Jones. “Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?” Eur Urol 65, no. 5 (May 2014): 873–74. https://doi.org/10.1016/j.eururo.2013.11.033.
    Full Text Link to Item
  - Harrison, Michael R., Bradford R. Hirsch, Daniel J. George, Mark S. Walker, Connie Chen, Beata Korytowsky, Edward Stepanski, and Amy P. Abernethy. “Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry.” J Oncol Pract 10, no. 2 (March 2014): e63–72. https://doi.org/10.1200/JOP.2013.001180.
    Full Text Link to Item
  - Hirsch, Bradford R., Daniel J. George, and Michael R. Harrison. “Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?” Clin Adv Hematol Oncol 12, no. 3 (March 2014): 163–71.
    Link to Item
  - Harrison, Michael R., Daniel J. George, Mark S. Walker, Connie Chen, Beata Korytowsky, Donald T. Kirkendall, Edward J. Stepanski, and Amy P. Abernethy. “"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.” Clin Genitourin Cancer 11, no. 4 (December 2013): 441–50. https://doi.org/10.1016/j.clgc.2013.05.002.
    Full Text Link to Item
  - George, Daniel J., Andrew J. Armstrong, and Michael R. Harrison. “Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary.” Clin Adv Hematol Oncol 11 Suppl 14, no. 9 (September 2013): 16–22.
    Link to Item
  - Inman, Brant A., Michael R. Harrison, and Daniel J. George. “Novel immunotherapeutic strategies in development for renal cell carcinoma.” Eur Urol 63, no. 5 (May 2013): 881–89. https://doi.org/10.1016/j.eururo.2012.10.006.
    Full Text Link to Item
  - Antonarakis, Emmanuel S., Elisabeth I. Heath, Edwin M. Posadas, Evan Y. Yu, Michael R. Harrison, Justine Y. Bruce, Steve Y. Cho, et al. “A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.” Cancer Chemother Pharmacol 71, no. 4 (April 2013): 883–92. https://doi.org/10.1007/s00280-013-2079-z.
    Full Text Link to Item
  - Turnbull, James D., Julien Cobert, Tracy Jaffe, Michael R. Harrison, Daniel J. George, and Andrew J. Armstrong. “Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.” Clin Genitourin Cancer 11, no. 1 (March 2013): 45–50. https://doi.org/10.1016/j.clgc.2012.06.001.
    Full Text Link to Item
  - Harrison, Michael R., Terence Z. Wong, Andrew J. Armstrong, and Daniel J. George. “Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.” Cancer Manag Res 5 (2013): 1–14. https://doi.org/10.2147/CMAR.S25537.
    Full Text Link to Item
  - Armstrong, A. J., J. D. Turnbull, J. Cobert, T. Jaffe, M. R. Harrison, and D. J. George. “Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 435. https://doi.org/10.1200/jco.2012.30.5_suppl.435.
    Full Text Link to Item
  - Harrison, M. R., D. J. George, M. S. Walker, L. L. Hudson, C. Chen, B. Korytowsky, E. J. Stepanski, and A. P. Abernethy. “Outcomes of "real world" treatment for metastatic renal cell carcinoma (mRCC).” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 406.
    Link to Item
  - Harrison, Michael Roger, Daniel J. George, Mark S. Walker, Lori L. Hudson, Connie Chen, Beata Korytowsky, Edward J. Stepanski, and Amy P. Abernethy. “Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC).” Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 406–406. https://doi.org/10.1200/jco.2012.30.5_suppl.406.
    Full Text
  - Liu, Glenn, Robert Jeraj, Matt Vanderhoek, Scott Perlman, Jill Kolesar, Michael Harrison, Urban Simoncic, et al. “Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.” Clin Cancer Res 17, no. 24 (December 15, 2011): 7634–44. https://doi.org/10.1158/1078-0432.CCR-11-1677.
    Full Text Link to Item
  - Harrison, M. R., and D. J. George. “Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) resistance in metastatic renal cell carcinoma (mRCC): Possible mechanisms and clinical approaches.” European Journal of Clinical and Medical Oncology 3, no. 4 (December 1, 2011): 1–9.
  - Harrison, Michael R., Noah M. Hahn, Roberto Pili, William K. Oh, Hans Hammers, Christopher Sweeney, Kyungmann Kim, et al. “A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).” Invest New Drugs 29, no. 6 (December 2011): 1465–74. https://doi.org/10.1007/s10637-010-9455-x.
    Full Text Link to Item
  - Harrison, Michael R., and Daniel J. George. “Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.” Clin Cancer Res 17, no. 18 (September 15, 2011): 5841–43. https://doi.org/10.1158/1078-0432.CCR-11-1768.
    Full Text Link to Item
  - Chao, B. H., M. R. Harrison, J. Kolesar, M. Vanderhoek, S. Perlman, J. C. Eickhoff, L. Carmichael, et al. “Pharmacodynamic and pharmacokinetic characterization of tumor proliferation during acute sunitinib (SU) withdrawal.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): e13556–e13556. https://doi.org/10.1200/jco.2011.29.15_suppl.e13556.
    Full Text
  - Harrison, M. R., R. Jeraj, H. J. Hammers, M. N. Stein, A. Andrei, S. Perlman, J. Kolesar, et al. “Phase I pharmacodynamic trial of sequential sunitinib (SU) with bevacizumab (bev) in patients with renal cell carcinoma (mRCC) and other advanced solid malignancies.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): e13503–e13503. https://doi.org/10.1200/jco.2011.29.15_suppl.e13503.
    Full Text
  - Harrison, Michael R. “Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?” Clin Med Insights Oncol 5 (2011): 349–64. https://doi.org/10.4137/CMO.S6087.
    Full Text Link to Item
  - Lang, Joshua M., and Michael R. Harrison. “Pazopanib for the treatment of patients with advanced renal cell carcinoma.” Clin Med Insights Oncol 4 (October 1, 2010): 95–105. https://doi.org/10.4137/CMO.S4088.
    Full Text Link to Item
  - Harrison, M. R., R. Jeraj, M. Vanderhoek, U. Simoncic, S. Perlman, J. Kolesar, J. C. Eickhoff, D. B. Alberti, G. Wilding, and G. Liu. “Characterization of proliferative rebound during drug holiday by FLT-PET imaging in patients treated with sunitinib (SU).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 3094–3094. https://doi.org/10.1200/jco.2010.28.15_suppl.3094.
    Full Text
  - Jeraj, R., G. Liu, U. Simoncic, M. Vanderhoek, S. Perlman, D. B. Alberti, M. R. Harrison, and G. Wilding. “Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 3050–3050. https://doi.org/10.1200/jco.2010.28.15_suppl.3050.
    Full Text
  - Harrison, Michael R., Wei Huang, Glenn Liu, and Jason Gee. “Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor.” Oncology (Williston Park) 23, no. 9 (August 2009): 792–95.
    Link to Item
  - Harrison, Michael R., Kyle D. Holen, and Glenn Liu. “Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.” Clin Adv Hematol Oncol 7, no. 1 (January 2009): 54–64.
    Link to Item
  - Harrison, M. R., N. Hahn, R. Pili, W. K. Oh, K. Kim, G. Wilding, C. J. Sweeney, C. Sidor, J. Arnott, and G. Liu. “Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 5173–5173. https://doi.org/10.1200/jco.2008.26.15_suppl.5173.
    Full Text
  - Farout, L., M. C. Lamare, C. Cardozo, M. Harrisson, Y. Briand, and M. Briand. “Distribution of proteasomes and of the five proteolytic activities in rat tissues.” Arch Biochem Biophys 374, no. 2 (February 15, 2000): 207–12. https://doi.org/10.1006/abbi.1999.1585.
    Full Text Link to Item
  - Ramalingam, sundhar, David Sermer, Rajan Gupta, Patrick Healy, Yuan Wu, Daniel George, Andrew Armstrong, and M. R. Harrison. “Changes in skeletal muscle cross sectional area (CSA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZ).” Journal of Clinical Oncology 34 (n.d.). https://doi.org/10.1200/JCO.2016.34.15\_suppl.e16601.
    Full Text Link to Item
- Book Sections
  - Harrison, M. R., T. Zhang, M. A. McNamara, and B. A. Inman. “Urologic Malignancies.” In Immune Checkpoint Inhibitors in Cancer, 115–33, 2019. https://doi.org/10.1016/B978-0-323-54948-6.00006-8.
    Full Text
  - McNamara, M. A., T. Zhang, M. R. Harrison, and D. J. George. “Cancer of the Kidney.” In Abeloff’s Clinical Oncology, 1361-1381.e4, 2019. https://doi.org/10.1016/B978-0-323-47674-4.00079-7.
    Full Text
  - Gilstrap, L., M. Harrison, G. G. Kimmick, and A. Nohria. “Management of chemotherapy-associated cardiomyopathy.” In Cardio-Oncology: The Clinical Overlap of Cancer and Heart Disease, 81–104, 2017. https://doi.org/10.1007/978-3-319-43096-6_4.
    Full Text
- Conference Papers
  - George, D. J., E. Moore, G. C. Blobe, N. DeVito, B. A. Hanks, M. R. Harrison, C. J. Hoimes, et al. “923P Molecular classification of cancers of unknown primary expands and refines treatment options.” In Annals of Oncology, 33:S968–69. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.1048.
    Full Text
  - Broughton, Edward I., Gary D. Steinberg, Michael Roger Harrison, Julia Braverman, Dena H. Jaffe, Oliver Will, Steven S. Senglaub, Kristen King-Concialdi, and Kathleen Beusterien. “Effect of neoadjuvant chemotherapy (NAC) on patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma (MIUC): A multi-country discrete choice experiment (DCE).” In Journal of Clinical Oncology, 40:454–454. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.454.
    Full Text
  - Chen, Yu-Wei, Matthew D. Tucker, Landon Carter Brown, Hesham Abdallah Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong, Katy Beckermann, et al. “Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Dzimitrowicz, Hannah Elizabeth, Fides Schwartz, Jordan Infield, Dylan Zhang, Ethan Ho, Yuan Wu, Rajan T. Gupta, and Michael Roger Harrison. “Body composition in patients with metastatic renal cell carcinoma receiving ipilimumab plus nivolumab.” In Journal of Clinical Oncology, 40:E16517–E16517, 2022.
    Link to Item
  - Koontz, B. F., K. E. Hoffman, T. Oyekunle, D. J. George, T. Zhang, W. R. Berry, W. R. Lee, et al. “Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.” In International Journal of Radiation Oncology, Biology, Physics, 111:e281, 2021. https://doi.org/10.1016/j.ijrobp.2021.07.902.
    Full Text
  - McGregor, Bradley Alexander, Arjun Vasant Balar, Jonathan E. Rosenberg, Michiel Simon Van Der Heijden, Se Hoon Park, Jae-Lyun Lee, Takahiro Kojima, et al. “Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.” In Journal of Clinical Oncology, 39:4524–4524. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.4524.
    Full Text
  - Tucker, Matthew D., Landon Carter Brown, Chester Kao, Nathan Hirshman, Emily Noelle Kinsey, Yu-Wei Chen, Kristin Kathleen Ancell, et al. “Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 39:4563–4563. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.4563.
    Full Text
  - Balar, Arjun Vasant, Bradley Alexander McGregor, Jonathan E. Rosenberg, Michiel Simon Van Der Heijden, Se Hoon Park, Jae-Lyun Lee, Michael Roger Harrison, et al. “EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.” In Journal of Clinical Oncology, 39:394–394. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.394.
    Full Text
  - Brown, Landon Carter, Susan Halabi, Michael Sandon Humeniuk, Yuan Wu, Taofik Oyekunle, Jiaoti Huang, Monika Anand, et al. “Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.” In Journal of Clinical Oncology, 39:89–89. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.89.
    Full Text
  - Harrison, Michael Roger, David Bartlett, Tian Zhang, Andrew J. Armstrong, Aubrie Coburn, Brian Coyne, Monika Anand, et al. “ASSET: Alternative schedule sunitinib in metastatic renal cell carcinoma (RCC)—Cardiopulmonary exercise testing (CPET).” In Journal of Clinical Oncology, 39:300–300. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.300.
    Full Text
  - Hutson, Thomas E., Bradley Curtis Carthon, Jeffrey Yorio, Sunil Babu, Heidi Ann McKean, Ivor John Percent, Scott S. Tykodi, et al. “Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the CheckMate 920 trial.” In Journal of Clinical Oncology, 39:315–315. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.315.
    Full Text
  - Rose, Tracy L., Michael Roger Harrison, Allison Mary Deal, Chelsea K. Osterman, Sundhar Ramalingam, Young E. Whang, Blaine Y. Brower, et al. “Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).” In Journal of Clinical Oncology, 39:396–396. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.396.
    Full Text
  - Tykodi, Scott S., Lucio N. Gordan, Robert S. Alter, Edward Arrowsmith, Michael Roger Harrison, Ivor John Percent, Rakesh Singal, et al. “Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.” In Journal of Clinical Oncology, 39:309–309. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.309.
    Full Text
  - Zhang, Tian, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart Frizzell, Luke T. Nordquist, et al. “Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).” In Journal of Clinical Oncology, 39:90–90. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.90.
    Full Text
  - Brown, Landon Carter, Kunal Desai, Chester Kao, Emily Noelle Kinsey, Patrick Healy, Julie Kephart, Michael Roger Harrison, et al. “A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Desai, Kunal, Landon Carter Brown, Wei Wei, Kimberly D. Allman, Allison Martin, Laura S. Wood, Shilpa Gupta, et al. “Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Dzimitrowicz, Hannah Elizabeth, Elizabeth Esterberg, LaStella Miles, Giovanni Zanotti, Azah Borham, and Michael Roger Harrison. “Provider referral patterns following nephrectomy in high-risk locoregional renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Hannah Berg, et al. “Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Zhang, Tian, Yuan Wu, Anika Agarwal, Mark D. Starr, Marco Reyes-Martinez, Monika Anand, Daniella Runyambo, et al. “Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Kao, Chester, Eric Powers, Michael B. Datto, Michelle Green, Michael Roger Harrison, Andrew J. Armstrong, Daniel J. George, Jeffrey Melson Clarke, John H. Strickler, and Tian Zhang. “Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Grimm, Marc-Oliver, David F. Mcdermott, Toni K. Choueiri, Robert J. Motzer, Osvaldo Aren Frontera, Saby George, Thomas Powles, et al. “Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC).” In Oncology Research and Treatment, 43:70–71. KARGER, 2020.
    Link to Item
  - Brown, Landon Carter, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew D. Tucker, Matthew Labriola, et al. “Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Garmezy, Benjamin, Tian Zhang, Andrew Leonard Laccetti, Minas P. Economides, Amishi Yogesh Shah, Nizar M. Tannir, Eric Jonasch, et al. “Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Harrison, Michael R., Mohamdod Alzer, Hayden K. Giuliani, Jack Carver, Alex R. Lucas, David B. Bartlett, Matthew I. Milowsky, et al. “Muscle Cross-sectional Area Improves With Home-based Training During Metastatic Castration-resistant Prostate Cancer.” In Medicine and Science in Sports and Exercise, 52:146–146, 2020.
    Link to Item
  - Stopforth, Cameron K., Mohamdod Alzer, Jack Carver, Alexander Lucas, Young Whang, Matthew Milowsky, David B. Bartlett, et al. “BODY COMPOSITION, PHYSICAL FUNCTION AND QUALITY OF LIFE ACROSS DIFFERENT STAGES OF PROSTATE CANCER: A CROSS-SECTIONAL ANALYSIS.” In Medicine and Science in Sports and Exercise, 52:981–981, 2020.
    Link to Item
  - Kinsey, Emily, Landon Brown, Chester Kao, Patrick Healy, Michael Harrison, Megan McNamara, Andrew Armstrong, Sundhar Ramalingham, Daniel George, and Tian Zhang. “Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC).” In Journal for Immunotherapy of Cancer, Vol. 7. BMC, 2019.
    Link to Item
  - Harrison, Michael, Meredith Regan, Michael Atkins, Sumati Rao, Shuo Yang, Jennifer Johansen, Ella Du, et al. “Economic benefits associated with treatment-free survival of immuno-oncology agents among untreated patients with intermediate/poor-risk advanced or metastatic renal cell carcinoma.” In Journal for Immunotherapy of Cancer, Vol. 7. BMC, 2019.
    Link to Item
  - Hanson, Erik D., Jackson L. Carver, Alexander Lucas, Michael Bass, Mohamdod Alzer, Young Whang, Michael Harrison, Matthew I. Milowsky, Rhonda L. Bitting, and Claudio L. Battaglini. “High Adherence To Home-Based Exercise Improves Muscle Strength And Cardiorespiratory Fitness With Advanced Prostate Cancer.” In Medicine &Amp; Science in Sports &Amp; Exercise, 51:6–7. Ovid Technologies (Wolters Kluwer Health), 2019. https://doi.org/10.1249/01.mss.0000560506.05468.17.
    Full Text
  - Chanza, Nieves Martinez, Wanling Xie, Majd Issa, Hannah Elizabeth Dzimitrowicz, Abhishek Tripathi, Benoit Beuselinck, Elaine Tat Lam, et al. “Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
    Link to Item
  - Autio, Karen A., Emmanuel S. Antonarakis, Raymond Baser, Mark N. Stein, Daniel H. Shevrin, Ulka N. Vaishampayan, Tina M. Mayer, et al. “Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC).” In Journal of Clinical Oncology, 37:5080–5080. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5080.
    Full Text
  - Mara, Alexandria, Jason Zhu, Yuan Wu, Tom Callis, Shan Yang, Edward D. Esplin, Robert L. Nussbaum, et al. “Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.” In Journal of Clinical Oncology, 37:5062–5062. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5062.
    Full Text
  - McDermott, David F., Toni K. Choueiri, Robert J. Motzer, Osvaldo Rudy Aren, Saby George, Thomas Powles, Frede Donskov, et al. “CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.” In Journal of Clinical Oncology, 37:4513–4513. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.4513.
    Full Text
  - Zhang, Tian, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart Frizzell, Julia Rasmussen, et al. “A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).” In Journal of Clinical Oncology, 37:TPS5097–TPS5097. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps5097.
    Full Text
  - Zhu, Jason, Matthew D. Tucker, Chester Kao, Matthew Labriola, Sachica Cheris, Michael B. Datto, Yuan Wu, et al. “Immune checkpoint inhibitor response in tumors with LRP1B variants.” In Journal of Clinical Oncology, 37:e14291–e14291. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14291.
    Full Text
  - Armstrong, Andrew J., Rhonda L. Bitting, Patrick Healy, Daniel J. George, Sung Kim, Tina M. Mayer, Carolyn Winters, et al. “Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.” In Journal of Clinical Oncology, 37:29–29. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.29.
    Full Text
  - Harrison, Michael Roger, Michel Khouri, Andrew J. Armstrong, Tian Zhang, Megan Ann McNamara, Monika Anand, Ellen Bratt, et al. “PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).” In Journal of Clinical Oncology, 37:281–281. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.281.
    Full Text
  - McDermott, David F., Brian I. Rini, Robert J. Motzer, Nizar M. Tannir, Bernard Escudier, Christian K. Kollmannsberger, Hans J. Hammers, et al. “Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.” In Journal of Clinical Oncology, 37:564–564. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.564.
    Full Text
  - Tucker, Matthew D., Jason Zhu, William R. Berry, Sundhar Ramalingam, Tian Zhang, Michael Roger Harrison, Yuan Wu, Patrick Healy, Daniel J. George, and Andrew J. Armstrong. “Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:172–172. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.172.
    Full Text
  - Zhang, Tian, Janet S. Staats, Cliburn Chan, Ajjai Shivaram Alva, Peter H. O’Donnell, Michael Roger Harrison, Kristen A. Batich, Veerendra Munugalavadla, Daniel J. George, and Kent J. Weinhold. “Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).” In Journal of Clinical Oncology, 37:357–357. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.357.
    Full Text
  - Koontz, B. F., K. E. Hoffman, P. Healy, D. J. George, M. R. Harrison, T. Zhang, W. R. Lee, et al. “Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 102:S100–S100. Elsevier BV, 2018. https://doi.org/10.1016/j.ijrobp.2018.06.256.
    Full Text
  - McDermott, D. F., B. I. Rini, R. J. Motzer, N. M. Tannir, B. Escudier, C. K. Kollmannsberger, H. J. Hammers, et al. “Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis.” In Ann Oncol, 29 Suppl 8:viii309, 2018. https://doi.org/10.1093/annonc/mdy283.083.
    Full Text Link to Item
  - Harrison, M. R., P. G. Davis, M. G. Khouri, R. T. Gupta, A. J. Armstrong, M. A. McNamara, T. Zhang, et al. “EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC).” In Ann Oncol, 29 Suppl 8:viii623–24, 2018. https://doi.org/10.1093/annonc/mdy300.064.
    Full Text Link to Item
  - George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.
    Link to Item
  - Autio, Karen A., Emmanuel S. Antonarakis, Tina M. Mayer, Ulka N. Vaishampayan, Daniel H. Shevrin, Michael Roger Harrison, Scott T. Tagawa, et al. “Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP).” In Journal of Clinical Oncology, 36:5016–5016. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5016.
    Full Text
  - Zhang, Tian, Janet S. Staats, Cliburn Chan, Michael Roger Harrison, Peter H. O’Donnell, Kristen A. Batich, Tianling Chen, et al. “Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).” In Journal of Clinical Oncology, 36:4533–4533. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4533.
    Full Text
  - Hanlon, Ashley, Steven Fleming, Ann S. Hamilton, Michaela Ann Dinan, Chiara Melloni, Michael Roger Harrison, Michel Khouri, et al. “Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT).” In Journal of Clinical Oncology, 36:127–127. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.7_suppl.127.
    Full Text
  - Koontz, Bridget F., Karen E. Hoffman, Patrick Healy, Daniel J. George, Michael Roger Harrison, Tian Zhang, W Robert Lee, et al. “Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.” In Journal of Clinical Oncology, 36:11–11. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.11.
    Full Text
  - Humeniuk, Michael Sandon, Rajan T. Gupta, Megan Ann McNamara, Sundhar Ramalingam, Michael Roger Harrison, Daniel J. George, Yuan Wu, Patrick Healy, and Andrew J. Armstrong. “Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer.” In Journal of Clinical Oncology, 35:e16532–e16532. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e16532.
    Full Text
  - Armstrong, Andrew J., Michael S. Humeniuk, Patrick Healy, Russell Szmulewitz, Carolyn Winters, Julie Kephart, Michael R. Harrison, et al. “Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.” In Prostate, 77:385–95, 2017. https://doi.org/10.1002/pros.23277.
    Full Text Link to Item
  - Harrison, Michael Roger, Nrupen Anjan Bhavsar, Steven Paul Wolf, Brian Addis Costello, Ulka N. Vaishampayan, Christos Kyriakopoulos, Walter Michael Stadler, et al. “Prospective front-line management patterns in the Real World Metastatic Renal Cell Cancer (MaRCC) Registry.” In Journal of Clinical Oncology, 34:e16097–e16097. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e16097.
    Full Text
  - Harrison, Michael Roger, Nrupen Anjan Bhavsar, Steven Paul Wolf, Brian Addis Costello, Ulka N. Vaishampayan, Christos Kyriakopoulos, Walter Michael Stadler, et al. “Deferred systemic therapy (DST) in the prospective metastatic renal cell cancer (MaRCC) registry.” In Journal of Clinical Oncology, 34:e16084–e16084. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e16084.
    Full Text
  - George, Daniel J., Susan Halabi, Patrick Healy, Sarah Gemberling, Carolyn Winters, Kelly Mundy, Michael Roger Harrison, Russell Zelig Szmulewitz, and Andrew J. Armstrong. “Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 34:275–275. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.275.
    Full Text
  - Harrison, Michael Roger, Nrupen Anjan Bhavsar, Steven Paul Wolf, Brian Addis Costello, Walter Michael Stadler, Hans J. Hammers, Ulka N. Vaishampayan, et al. “Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry.” In Journal of Clinical Oncology, 34:617–617. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.617.
    Full Text
  - Kyriakopoulos, Christos, Michael Roger Harrison, Nrupen Anjan Bhavsar, Steven Paul Wolf, Brian Addis Costello, Walter Michael Stadler, Hans J. Hammers, et al. “Physician treatment selection in the prospective Metastatic Renal Cell Cancer (MaRCC) Registry.” In Journal of Clinical Oncology, 34:563–563. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.563.
    Full Text
  - Bhavsar, Nrupen A., Michael R. Harrison, Bradford R. Hirsch, Patricia Creel, Steve P. Wolf, Greg P. Samsa, Eric M. Richardson, Kathleen A. Johnson, Azah Borham, and Daniel J. George. “The metastatic renal cell carcinoma (MaRCC) Registry: a prospective academic and community-based study of metastatic renal cell cancer patients.” In Bju International, 116:3–4. WILEY-BLACKWELL, 2015.
    Link to Item
  - Costello, Brian A., Michael R. Harrison, Nrupen A. Bhavsar, Steven P. Wolf, Christos E. Kyriakopoulos, Walter M. Stadler, Hans Joerg Hammers, et al. “Physician treatment selection in the prospective metastatic renal cell cancer (MaRCC) registry.” In Bju International, 116:7–7. WILEY-BLACKWELL, 2015.
    Link to Item
  - Harrison, Michael R., Nrupen A. Bhavsar, Steve P. Wolf, Brian A. Costello, Walter M. Stadler, Hans Joerg Hammers, Ulka Vaishampayan, et al. “Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry.” In Bju International, 116:12–12. WILEY-BLACKWELL, 2015.
    Link to Item
  - Choueiri, Toni K., Mayer N. Fishman, Bernard Escudier, David F. McDermott, Harriet M. Kluger, Walter Michael Stadler, Jose Luis Perez-Gracia, et al. “Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, John H. Strickler, et al. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Plimack, Elizabeth R., Hans J. Hammers, Brian I. Rini, David F. McDermott, Bruce Redman, Timothy Kuzel, Michael Roger Harrison, et al. “Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 33:4553–4553. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.4553.
    Full Text
  - Bhavsar, N. A., M. R. Harrison, L. J. Howie, A. J. Armstrong, K. Davis, Q. Chen, M. R. Pupa, A. Abernethy, D. J. George, and B. R. Hirsch. “1072PEXPERIENCE OF PATIENTS TREATED WITH SIPULEUCEL-T IN AN ACADEMIC SETTING.” In Ann Oncol, 25:iv369–70, 2014. https://doi.org/10.1093/annonc/mdu342.25.
    Full Text Link to Item
  - Motzer, R. J., B. I. Rini, D. F. McDermott, B. Redman, T. Kuzel, M. R. Harrison, U. N. Vaishampayan, et al. “810ORANDOMIZED, DOSE-RANGING PHASE II TRIAL OF NIVOLUMAB FOR METASTATIC RENAL CELL CARCINOMA (MRCC).” In Annals of Oncology : Official Journal of the European Society for Medical Oncology, 25:iv281, 2014.
  - Thomas, Reena Mary, Adva Eisenberg, Michael Harrison, and Larry Gene Moss. “Ectopic Secretion of ACTH from a Neuroendocrine Differentiated Metastatic Prostatic Carcinoma a Rare Phenomenon Presenting Unique Challenges in Management.” In Endocrine Reviews, Vol. 35. ENDOCRINE SOC, 2014.
    Link to Item
  - Choueiri, Toni K., Mayer N. Fishman, Bernard J. Escudier, Jenny J. Kim, Harriet M. Kluger, Walter Michael Stadler, Jose Luis Perez-Gracia, et al. “Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.” In Journal of Clinical Oncology, Vol. 32. AMER SOC CLINICAL ONCOLOGY, 2014.
    Link to Item
  - Mitchell, Aaron Philip, Michael Roger Harrison, Daniel J. George, Amy Pickar Abernethy, Mark S. Walker, and Bradford Richard Hirsch. “Clinical trial subjects compared to "real world" patients: Generalizability of renal cell carcinoma trials.” In Journal of Clinical Oncology, 32:6510–6510. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.6510.
    Full Text
  - Hirsch, B., M. R. Harrison, M. S. Walker, L. Roe, C. Chen, B. Korytowsky, E. J. Stepanski, D. J. George, and A. P. Abernethy. “Adverse events among patients treated for metastatic renal cell carcinoma (mRCC): Data from a real world, multicenter registry.” In European Journal of Cancer, 49:S661–S661. ELSEVIER SCI LTD, 2013.
    Link to Item
  - Antonarakis, Emmanuel S., Elisabeth I. Heath, Edwin M. Posadas, Michael Roger Harrison, Justine Yang Bruce, Evan Y. Yu, Steve Y. Cho, et al. “A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Harrison, Michael Roger, Daniel J. George, Mark S. Walker, Lori L. Hudson, Connie Chen, Beata Korytowsky, Edward J. Stepanski, and Amy Pickar Abernethy. “Beyond metastatic renal cell carcinoma (mRCC) clinical trials: Targeted therapy use and overall survival in community oncology clinics.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - George, D. J., M. S. Walker, L. L. Hudson, C. Chen, B. Korytowsky, M. R. Harrison, E. Stepanski, and A. P. Abernethy. “'Real World' treatment of metastatic renal cell carcinoma (mRCC) in community and academic settings.” In Bju International, 109:5–5. WILEY-BLACKWELL, 2012.
    Link to Item
  - Harrison, M. R., R. Jeraj, S. Perlman, M. Vanderhoek, J. Kolesar, J. Eickhoff, D. Alberti, G. Wilding, and G. Liu. “Use of VEGF Tyrosine Kinase Inhibitor Withdrawal to Enhance Cytotoxic Chemotherapy Effect in Prostate Cancer,” 2008.
  - Harrison, M. R., B. Hirsch, M. S. Walker, L. Roe, C. Chen, B. Korytowsky, E. J. Stepanski, D. J. George, and A. P. Abernethy. “Adverse events (AEs) by age: data from a real world, multicenter registry of patients treated for metastatic renal cell carcinoma (mRCC),” n.d.
  - Harrison, M. R., R. Jeraj, M. Vanderhoek, U. Simoncic, S. Perlman, D. B. D. Alberti, G. Wilding, and G. Liu. “Characterization of proliferative rebound by FLT PET imaging during the off-drug period of the cycle on two different schedules of sunitinib (SU),” n.d.
  - Harrison, M. R., R. Pili, T. Logan, G. Wilding, J. Eickhoff, C. Sidor, M. J. Staab, J. Arnott, and G. Liu. “Phase II Study of 2-Methoxyestradiol NanoCrystal® Dispersion (2ME2) Alone and in Combination with Sunitinib (SU) in Patients with Metastatic Renal Cell Carcinoma (mRCC) Progressing on SU,” n.d.
  - Liu, G., C. Morrison, A. Dattawadkar, S. Perlman, S. Reeder, S. Fain, M. R. Harrison, J. Eickhoff, and R. Jeraj. “Positron Emission Tomography (PET) Imaging for Treatment Response Determination in Prostate Cancer Osseous Metastases,” n.d.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Conference Papers